| |
May 1 - 3, 2023 | Jersey City, NJ Don’t miss the opportunity to gain best practices in medical affairs strategy development and ensuring scientific materials are created and shared in a regulatory compliant manner to internal/external stakeholders and thought leaders. Take advantage of the Early Bird Rates, Register Today!
|
|
Today's Big NewsFeb 9, 2023 |
|
Tuesday, February 28, 2023 | 11am ET / 8am PT The heavy lifting for the pharmaceutical industry to comply with the November 2023 DSCSA go-live date is still ongoing. One item now finalized is to ensure that the required data exchange through the supply chain is only done with trusted, authorized, and registered trading partners. Join us for this discussion to stay up-to-date on this important legislation and be prepared for compliance. Register now.
|
|
| By Max Bayer AbbVie is setting the stage for an aggressive M&A push to fill the revenue vacuum left by Humira, with CEO Richard Gonzalez telling investors to expect a move if the shoe fits. |
|
|
|
By Angus Liu Pascal Soriot’s pledge to boost AstraZeneca’s revenue to more than $40 billion by 2023 has been met early, and the CEO is already on to his next ambitious goal—15 new drugs by 2030. |
By Andrea Park Under the terms of the deal, Abbott will pay out $20 for each share of Cardiovascular Systems—about a 50% premium over the company’s share price before the acquisition was announced. |
By Fraiser Kansteiner When it comes to GSK's new HIF-PH inhibitor Jesduvroq, some nephrologists are excited to have another treatment option in the anemia of CKD armamentarium, Spherix Global Insights reports. Still, others have taken a more cautious approach, expressing disappointment with the “limited utility" of the drug's "restrictive label.” |
|
Evidation and Fierce Biotech conducted a survey of industry professionals to gather insights on the role integrated evidence strategies play in their businesses, as well as the impact of these strategies in helping to deliver better health outcomes. Access the findings from this important survey now.
|
|
By Andrea Park Just a few weeks after being newly reborn as a standalone public company, GE HealthCare is already going through a growth spurt. |
By James Waldron Scroll through AstraZeneca’s pipeline of new drug candidates in development and there remains one glaring omission. The Big Pharma that brought one of the world’s most widely used COVID-19 shots to market doesn’t have any more vaccines in development and only has a single new immune therapy in the clinic. |
By Andrea Park Fresh off publishing an earnings report showing a two-thirds drop in sales of its COVID-19 tests in 2022, Thermo Fisher Scientific has begun laying off hundreds of workers at three manufacturing sites in California. |
By Kevin Dunleavy Four years after scoring an approval to treat diabetic retinopathy, Regeneron’s Eylea has gained an FDA nod for the infant version of the disorder despite less-than-ideal clinical data. |
By Annalee Armstrong Last week, Magenta Therapeutics announced plans to close down. This week, executive leadership and staff are being handed their pink slips. |
By Conor Hale Though the Biden administration is set to declare an official end to the COVID-19 public health emergency this May, that won’t necessarily bring immediate changes in the U.S. landscape of coronavirus tests, treatments and vaccines. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss what we can expect from the obesity market in 2023. We also recap the drugs approved last year. |
|
|---|
|
|
|
The global demand for biologics is projected to increase considerably by 2030, but the challenges, risks, and costs are also growing. For pharma companies looking to bring a new biologic to market, meeting clinical trial milestones can be difficult. To access important insights, download this executive summary now.
|
|
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| WhitepaperThis paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
| WhitepaperExploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
| WhitepaperLearn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
